In immuno-oncology, co-inhibitory molecules such as PD-1 and CTLA-4 play key roles in limiting antigen-responsiveness in T cells. These are primary targets for cancer immunotherapy (inhibition of their negative influence can reignite anti-tumour T cell immunity). In contrast, positive signalling through other molecules, such as OX-40, ICOS, or 4-1BB, can also enhance T cell function.
During an immune response, activated T cells undergo rapid expansion to tackle infection or disease as well as a whole host of other dynamic interactions (T cell/T cell and T cell/ antigen-presenting cells (APC)) which drives activity. Understanding the mechanisms of immune cell activation, proliferation and regulation is key to the development of novel and effective cancer immunotherapies.
An initial port of call for many Biotech and Pharma companies attempting to get their antibody or compounds to the clinic for cancer immunotherapy, will be to understand what happens when they put their treatment into either a whole blood assay, or more commonly, to assess the effects on isolated human peripheral blood mononuclear cells (PBMCs) in a PBMC assay.
Aquila’s activated human PBMC assay and T cell activation assays are plated in 96-well plate format for high throughput screening of multiple antibody/compound combinations concentrations. Analysis of treatment effect is achieved by determining cytokine levels by ELISA (e.g. IFN-γ) and/or assessment of proliferation (e.g. CFSE) and other activation/cellular markers by multi-colour flow cytometry).
Aquila can also run whole blood assays as required.
Contact us today to discuss your human PBMC or T cell stimulation study requirements.